Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV 및 mRNA-1273을 사용한 SARS CoV-2에 대한 이종 면역의 면역원성과 반응성Article Published on 2022-08-162022-09-11 Journal: Cell Reports Medicine [Category] SARS, 변종, 진단, 치료기술, [키워드] Ad5-nCoV analyzed Anti-spike Antibody Response BBIBP-CorV ChAdOx1 ChAdOx1 vaccine ChAdOx1-S Cohort Combination coronavirus disease Coronavirus disease 2019 Coverage COVID-19 evaluate Heterologous heterologous vaccination heterologous vaccine highest homologous humoral Humoral response IgG immunization immunogenicity Immunoglobulin Immunoglobulin G information Messenger RNA mRNA mRNA-1273 nCoV Neutralizing antibodies neutralizing antibodies. observation observé omicron Omicron variant Participants platform provide reactogenicity Region SARS CoV-2 SARS-CoV-2 second dose Serious Adverse Event Serious Adverse Events Sputnik V Support titers vaccination Vaccine virus neutralizing titer virus neutralizing titers [DOI] 10.1016/j.xcrm.2022.100706 PMC 바로가기 [Article Type] Article
The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021Observational Study Published on 2022-08-152022-10-04 Journal: The Medical journal of Australia [Category] 임상, [키워드] Active surveillance adjusted Administered adverse event anaphylaxis AstraZeneca BNT162b2 ChAdOx1 chronic inflammatory disease clinics Cohort Controlled COVID-19 COVID-19 vaccination COVID-19 vaccine demographic characteristics dose drug-related side effects and adverse reactions eight fatigue headache immunodeficiency Medical conditions men myalgia National obesity outcome Pain Pfizer-BioNTech proportion Prospective reported reported symptoms safety profile secondary setting Seven Side effect study period Surveillance underlying conditions vaccination vaccination. Vaccine women [DOI] 10.5694/mja2.51619 PMC 바로가기 [Article Type] Observational Study
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variantsChAdOx1 nCoV-19(AZD1222) 또는 nCoV-19-Beta(AZD2816)는 베타 델타 및 오미크론 변종으로부터 시리아 햄스터를 보호합니다.Article Published on 2022-08-082022-09-11 Journal: Nature Communications [Category] SARS, 변종, 진단, 치료기술, [키워드] Antibody titer AZD1222 Beta ChAdOx1 ChAdOx1 nCoV-19 clinical trials Delta delta variant Efficacy evaluate the effect full-length hamster hamsters Heterologous include inoculation lung Lungs Neutralizing antibody titer omicron post inoculation PROTECT Protective Protein real-world data reduced reduction in regimen S protein S proteins SARS-CoV-2 sequence sgRNA shown simian adenovirus-vectored vaccine single dose Substitution substitutions symptomatic disease the S protein vaccination Vaccine variant variants variants of concern vectored vaccine Viral virus VOCs Wuhan-1 [DOI] 10.1038/s41467-022-32248-6 PMC 바로가기 [Article Type] Article
Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administrationIV ChAdOx1 nCov-19 투여 후 혈소판 감소증 및 비장 혈소판 유도 면역 반응Article Published on 2022-08-042022-09-11 Journal: Blood [Category] SARS, 치료기술, 치료제, [키워드] accompanied acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adenovirus adenovirus vaccine adenovirus-based administration aggregate anatomic sites antibody antiplatelet antiplatelet antibody approach Autoimmune response Autoimmunity B-cell response binding ChAdOx1 ChAdOx1 nCoV-19 characterized circulating antibodies circulating antibody clinical entities Complication contribute coronavirus followed by glycoprotein heparin heparin-induced thrombocytopenia highlight immune response Immune thrombocytopenia in vitro in vivo model Intramuscular injection IV injection Macrophage macrophages marginal zone mechanism mice pathology Patient phagocytosed Platelet platelet activation platelet factor 4 Platelets potential mechanism prothrombotic state receptor SARS-CoV-2 severe acute respiratory syndrome Coronavirus spleen thrombocytopenia thrombosis Trigger vaccination Vaccine zone [DOI] 10.1182/blood.2021014712 PMC 바로가기 [Article Type] Article
The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2SARS-CoV-2에 의한 미래 감염에 대한 자연 감염 및 백신 유도 면역의 내구성Comparative Study Published on 2022-08-022022-09-12 Journal: Proceedings of the National Academy of Sciences of [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Ad26.COV2.S analysis anti-S IgG antibody Antibody Response applied BNT162b2 booster vaccination Breakthrough infection ChAdOx1 conditions COVID-19 distribution elicited Endemic evaluated exceeded expected future infection IgG Immunity Immunoglobulin Infection knowledge likelihood median Messenger RNA Moderna mRNA mRNA-1273 natural infection Oxford-AstraZeneca pandemic parameter peak Pfizer-BioNTech public health Quantitative relative SARS-CoV-2 trajectory vaccination Vaccine Vaccine-induced immunity vaccine-mediated immunity vaccine. Viral vector vaccine [DOI] 10.1073/pnas.2204336119 PMC 바로가기 [Article Type] Comparative Study
Long-Term Outcomes after Vaccine-Induced Thrombotic Thrombocytopenia백신 유도성 혈전성 혈소판 감소증 후 장기 결과Article Published on 2022-08-012022-09-11 Journal: Viruses [Category] SARS, 진단, 치료기술, [키워드] acute phase Adenovirus adenovirus-based affected antibody Anticoagulants anticoagulation appear Arterial thrombosis AZD1222 bleeding cerebral venous sinus thrombosis ChAdOx1 ChAdOx1 nCoV-19 Cohort Cohort studies cohort study Complication coronavirus Corticosteroids COVID-19 D-dimer detectable diagnosed Diagnosis died dimer Direct discharge discharged eculizumab effective elevated enrolled Follow-up hospital hospital discharge Immunoglobulin in some Intravenous immunoglobulin IVIG limit management nCoV neurological nine observation occurred one patient oral anticoagulant outcome Patient patients PF4 Platelet platelet activation positive prothrombotic condition remained respiratory respiratory syndrome coronavirus respiratory syndrome coronavirus 2 Safe SARS-CoV-2 serious complication Seven severe respiratory syndrome single-center Sinus thrombosis survived Symptom symptom onset syndrome the disease thrombocytopenia thromboembolic Thromboembolic event Thromboembolic events thrombosis thrombotic Thrombotic thrombocytopenia Treatment two patients vaccination vaccination. Vaccine venous venous sinus were given [DOI] 10.3390/v14081702 PMC 바로가기 [Article Type] Article
Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study심각한 동반이환이 있는 고령 인구의 혈청학적 COVID-19 백신 반응 및 내구성과 관련된 특성: 덴마크 전국 ENFORCE 연구Article Published on 2022-08-012022-09-12 Journal: Clinical microbiology and infection : the official [Category] MERS, SARS, 진단, [키워드] adjusted age antibody baseline ChAdOx1 Characteristics COVID-19 COVID-19 vaccination COVID-19 vaccine declined decrease defined enrolled first vaccination functional hyporesponsiveness identify IgG Immunity increasing age individual interquartile lack Level Male sex median age mRNA vaccine mRNA-1273 number of comorbidity older population outcomes parallel group participant Responder response risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination serological Sex spike vaccination. Vaccine vaccine dose vaccine response vaccine-induced antibodies vaccine-induced antibody waned were measured [DOI] 10.1016/j.cmi.2022.03.003 PMC 바로가기 [Article Type] Article
Genetic basis of sudden death after COVID-19 vaccination in ThailandResearch article Published on 2022-08-012022-10-05 Journal: Heart Rhythm [Category] 변종, 유전자 메커니즘, 진단, [키워드] 24 hour acute respiratory syndrome Brugada syndrome ChAdOx1 Cohort coronavirus coronavirus disease correlation COVID-19 COVID-19 pandemic COVID-19 vaccination database death died enrolled Exome Fever first dose Frequency Genetic genetics men morbidity and mortality objective Patient receiving recruited reduce Result SCN5A Sequencing Sequencing analysis Serious Adverse Events significantly higher Sudden unexplained death (SUD) underlying disease vaccination Vaccine vaccine dose variant [DOI] 10.1016/j.hrthm.2022.07.019 [Article Type] Research article
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessmentResearch article Published on 2022-08-012022-10-05 Journal: Vaccine [Category] COVID19(2023년), SARS, 비임상, [키워드] adenoviral vector Adenovirus administration Antigen approved assessment benefit Benefit/Risk booster capillary leak syndrome cell line Cellular immune response ChAdOx1 circumvent clinical evaluation clinical trial collaboration conducted COVID-19 COVID-19 vaccination Deletion dose effective Emergency use authorization evaluate evaluated expressing Extensive feature fevers Genetic Guillain-barrè syndrome Hemorrhagic HIV humoral immune response Immune thrombocytopenia impair Influenza key consideration malaria manuscript MERS-CoV New Nipah virus Oxford-AstraZeneca platform pre-existing immunity Prophylactic Prostate cancer Replication reported risk Safety SARS-CoV-2 Serious Adverse Event serotype surveillance data syndrome therapeutic thrombosis Tuberculosis University of Oxford Vaccine Vaccine development Vaccines vectored vaccine virus Zika [DOI] 10.1016/j.vaccine.2022.06.008 [Article Type] Research article
Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination이종 및 동종 SARS-CoV-2 백신 접종에서 세포 및 체액성 면역 반응의 상호 의존성Observational Study Published on 2022-08-012022-09-11 Journal: Allergy [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] Anti-spike Antibody avidity association avidity blood sample Blood samples BNT162b2 booster booster vaccination cellular Cellular immune response cellular immune responses ChAdOx1 ChAdOx1 nCoV-19 group healthcare worker Heterologous homologous humoral Humoral and cellular immune responses humoral immune response humoral responses IgG levels immune immune response immune responses immunization interferon interferon-γ nCoV Neutralizing antibodies neutralizing antibody no significant differences Observational cohort study SARS-CoV-2 SARS-CoV-2 vaccination secondary immunization significant difference significant differences Spike protein T-cell T-cell activation T-cell Response T-cell responses unlikely vaccination vaccination. [DOI] 10.1111/all.15247 PMC 바로가기 [Article Type] Observational Study